2021-10-06T13:29:18-05:00 2020-12-31 111986323 MARCUM LLP 1899 L STREET NW SUITE 850 WASHINGTON DC 20036 990 2020-01-01 520880522 FOUNDATION FOR CONTEMPORARY MENTAL HEALTH FOUN 2022967100 2112 F STREET NW NO 404 WASHINGTON DC 20037 DR HOWARD HOFFMAN PRESIDENT/CEO 2022967100 2021-10-06 1 DR HOWARD HOFFMAN 999009999 AARON M FOX P01365820 2022274000 2021-10-06 3 AAL1 IAL1 2020 2022-09-23 18:48:47Z DR HOWARD HOFFMAN 2112 F STREET NW NO 404 WASHINGTON DC 20037 3950479 0 X N/A X 1967 DC TO PROVIDE SUBSTANCE ABUSE TREATMENT AND EDUCATION IN THE WASHINGTON METROPOLITAN AREA. 5 4 48 4 0 0 199026 217570 3806173 3729722 3187 3187 207 0 4008593 3950479 0 0 0 0 3000863 2874629 0 0 0 1285311 1269157 4286174 4143786 -277581 -193307 1370322 1524794 450512 825572 919810 699222 X FOUNDATION FOR CONTEMPORARY MENTAL HEALTH (THE FOUNDATION) IS ORGANIZED TO PROVIDE SUBSTANCE ABUSE TREATMENT AND EDUCATION IN THE WASHINGTON METROPOLITAN AREA WITH A SPECIAL INTEREST IN SERVING INDIGENT, UNINSURED AND UNDER-INSURED POPULATIONS. 0 0 3923029 3729722 PIDARC IS A PRIVATE, NON-PROFIT, OUTPATIENT MEDICATION ASSISTANT TREATMENT (MAT) PROGRAM LOCATED IN METROPOLITAN WASHINGTON, DC. IN 2020, WE PROVIDED METHADONE TREATMENT AND COUNSELING SERVICES TO AN AVERAGE MONTHLY CENSUS OF 620 PATIENTS WITH OPIOID USE DISORDERS, MOST OF WHOM ARE UNINSURED OR UNDERINSURED INDIVIDUALS. IN ADDITION, PIDARC REMAINED COMMITTED TO PROVIDING LINKAGES FOR PATIENTS TO ADDRESS THEIR MEDICAL AND PSYCHOSOCIAL NEEDS. AS WITH ALL HEALTHCARE AGENCIES, IT WAS NECESSARY FOR PIDARC TO ADJUST ITS CLINICAL PROGRAMMING AND TREATMENT SCHEDULE IN 2020 TO ACCOMMODATE FEDERAL AND STATE SAFETY RECOMMENDATIONS AND MANDATES RELATED TO THE COVID-19 PANDEMIC. PIDARC WORKED WITH THE DISTRICT OF COLUMBIA'S DEPARTMENT OF BEHAVIORAL HEALTH TO ENSURE SOCIAL DISTANCING AND OTHER MANDATED REQUIREMENTS WERE MET, INCLUDING MASK-WEARING AND TEMPERATURE CHECKS FOR ALL STAFF AND PATIENTS ENTERING THE CLINIC, TO MITIGATE POTENTIAL SPREAD OF THE VIRUS AMONG PATIENTS AND STAFF TO THE EXTENT POSSIBLE. GROUP ACTIVITIES WERE ALSO MINIMIZED, A REVISED METHADONE DOSING SCHEDULE INCORPORATING INCREASED TAKE-HOME MEDICATIONS WAS IMPLEMENTED FOR QUALIFIED PATIENTS, AND TELE-COUNSELING SERVICES WERE INITIATED TO REDUCE THE NEED FOR FACE-TO-FACE CONTACTS. 217070 DISTRICT OPIOID TARGETED STRATEGIES - IN 2020 THE FOUNDATION UTILIZED A GRANT FROM THE DEPARTMENT OF BEHAVIORAL HEALTH FOR THE PURPOSE OF IDENTIFYING PATIENTS TO RECEIVE COMPREHENSIVE PHYSICALS, EKGS AND TB TESTS ANNUALLY AND LINKING THEM WITH PRIMARY CARE AND SPECIALTY SERVICES. THE GRANT PAID FOR SALARIES, BENEFITS AND ASSOCIATED OPERATIONAL AND ADMINISTRATIVE COSTS FOR TWO INDIVIDUALS TO WORK WITH THE PATIENTS ON A CASE MANAGEMENT BASIS TO SCHEDULE AND FOLLOW UP ON THEIR PARTICIPATION WHILE ALSO COLLECTING REQUIRED DATA. 4140099 1 1 0 0 0 0 0 0 0 0 1 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 8 0 1 48 1 0 0 0 0 0 0 0 0 0 0 0 0 X 5 4 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 0 0 DC X AUDREY CANNAMELA 2022967100 2112 F STREET NW NO 404 WASHINGTON DC 20037 DR HOWARD HOFFMAN PRESIDENT/CEO 40.00 X X 222008 0 21825 JOSHUA MUSS SECRETARY 1.00 X X 0 0 0 FRANCINE LEVINSON TREASURER 1.00 X X 0 0 0 CECELIA SCORAH DIRECTOR 1.00 X 0 0 0 BRAD SPENCER DIRECTOR 1.00 X 0 0 0 AUDREY CANNAMELA EXECUTIVE DIRECTOR 40.00 X 171550 0 18232 BRIAN CRISSMAN ASSISTANT DIRECTOR 40.00 X 120634 0 6784 514192 0 46841 3 0 1 0 MARCUM LLP 1899 L STREET NW SUITE 850 WASHINGTON DC 20036 ACCOUNTING/HR/TECH. SERVICES 213202 1 217570 217570 TREATMENT INCOME 900099 3729722 3729722 3729722 3187 3187 3950479 3729722 0 3187 433615 170684 262931 1998522 1910746 87776 43819 41855 1964 222559 188894 33665 176114 155649 20465 31987 31987 258444 27740 230704 6644 4907 1737 4375 2356 2019 140481 116792 23689 479272 333681 145591 1495 1495 23613 20609 3004 40842 8799 32043 TREATMENT 212406 212406 BAD DEBT EXPENSE 54996 54996 PROF. DEVELOPMENT 11550 11550 MEMBERSHIP DUES 2760 2760 292 874180 -873888 4143786 4140099 3687 0 135293 212736 286012 369113 412074 429466 65667 64504 330740 282445 70817 48295 377244 377465 23215 23215 1370322 1524794 313419 298646 50000 0 0 477931 87093 48995 450512 825572 X 919810 699222 919810 699222 1370322 1524794 -193307 -27281 0 X 0 0 0 X 640 39424 224561 199062 217570 681257 4195562 4386620 4030804 3806173 3729722 20148881 4196202 4426044 4255365 4005235 3947292 20830138 0 0 0 20830138 36257 35466 16440 3187 3187 94537 36257 35466 16440 3187 3187 94537 115 207 322 4232459 4461625 4271805 4008629 3950479 20924997 0.99550 0.99400 0.00450 0.00600 X SCHEDULE A, PART III, LINE 12, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2016 AMOUNT: $ 0. 2017 AMOUNT: $ 115. 2018 AMOUNT: $ 0. 2019 AMOUNT: $ 207. 2020 AMOUNT: $ 0. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 76372 58831 17541 169377 157110 12267 84991 66504 18487 48295 CERTIFICATES OF DEPOSIT 377465 F 377465 DEFERRED RENT LIABILITY 22329 CAPITAL LEASE OBLIGATION 26666 48995 X X 0 0 0 0 0 0 0 0 0 DR HOWARD HOFFMAN PRESIDENT/CEO 222008 0 0 0 0 0 9247 0 12578 0 243833 0 0 0 AUDREY CANNAMELA EXECUTIVE DIRECTOR 171550 0 0 0 0 0 7128 0 11104 0 189782 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B THE PRESIDENT/CEO REVIEWS THE DRAFT FEDERAL FORM 990 WITH THE EXECUTIVE COMMITTEE. THE FEDERAL FORM 990 IS THEN SIGNED AND FILED WITH THE INTERNAL REVENUE SERVICE. AFTER FINALIZATION, THE FINALIZED FORM 990 IS DISCUSSED AT THE NEXT MEETING OF THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 12C THE OFFICERS AND DIRECTORS ARE REQUIRED TO SIGN A DISCLOSURE FORM RELATED TO CONFLICTS OF INTEREST POLICY ON AN ANNUAL BASIS. THE DISCLOSURES ARE REVIEWED AND ANY POTENTIAL CONFLICTS ARE ADDRESSED ACCORDING TO THE FOUNDATION'S POLICY. 1. DUTY TO DISCLOSE. IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF THE FINANCIAL INTEREST AND BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS EITHER TO THE BOARD OF DIRECTORS OR TO MEMBERS OF COMMITTEES WITH GOVERNING BOARD DELEGATED POWERS CONSIDERING THE PROPOSED TRANSACTION OR ARRANGEMENT. 2. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, HE/SHE SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON BY THE MEMBERS PRESENT. 3. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST A. AN INTERESTED PERSON MAY MAKE A PRESENTATION AT THE BOARD OF DIRECTOR'S MEETING, BUT AFTER THE PRESENTATION, HE/SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF AND THE VOTE ON THE TRANSACTION OR ARRANGEMENT INVOLVING THE POSSIBLE CONFLICT OF INTEREST. B. THE PRESIDENT SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. IF THE POTENTIAL CONFLICT OF INTEREST INVOLVES THE PRESIDENT, THE TREASURER SHALL APPOINT AN INVESTIGATOR. ANY FINDINGS MADE BY THE APPOINTED INVESTIGATOR/COMMITTEE WILL BE PRESENTED TO THE BOARD OF DIRECTORS. C. AFTER EXERCISING DUE DILIGENCE, THE BOARD OF DIRECTORS SHALL DETERMINE WHETHER THE FOUNDATION CAN OBTAIN WITH REASONABLE EFFORTS A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. D. IF A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY POSSIBLE, THE BOARD OF DIRECTORS SHALL DETERMINE, BY A MAJORITY VOTE OF THE DISINTERESTED DIRECTORS, WHETHER THE TRANSACTION OR ARRANGEMENT IS IN THE FOUNDATION'S BEST INTEREST, FOR ITS OWN BENEFIT, AND WHETHER IT IS FAIR AND REASONABLE. IN CONFORMITY WITH THE ABOVE DETERMINATION IT SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT. 4. VIOLATIONS OF THE CONFLICTS OF INTEREST POLICY A. IF THE BOARD OF DIRECTORS HAS REASONABLE CAUSE TO BELIEVE ANY PERSON HAS FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, IT SHALL INFORM THAT PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD THAT PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING ANY RESPONSE AND AFTER MAKING FURTHER INVESTIGATION AS WARRANTED BY THE CIRCUMSTANCES, THE BOARD OF DIRECTORS DETERMINE THAT THE PERSON HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. FORM 990, PART VI, SECTION B, LINE 15A THE FOUNDATION USES A COMPENSATION COMMITTEE, A WRITTEN EMPLOYMENT CONTRACT, REQUIRES APPROVAL BY THE BOARD OF DIRECTORS, AND HAS CONTEMPORANEOUS WRITTEN SUBSTANTIATION OF THE DECISION-MAKING PROCESS FOR DETERMINING CEO COMPENSATION. FOR THE EXECUTIVE DIRECTOR, THE PRESIDENT/CEO PRESENTS A SUMMARY OF THE EXECUTIVE DIRECTOR'S ACTIVITIES AND ACCOMPLISHMENTS TO THE BOARD OF DIRECTOR'S COMPENSATION COMMITTEE AND WILL MAKE A RECOMMENDATION FOR COMPENSATION FOR BOARD APPROVAL. FORM 990, PART VI, SECTION C, LINE 19 THE FOUNDATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST.